The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index; 17 of the 59 sources its claims cite were checked for support.
Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries
Open accessAbstract
BACKGROUND: The WHO Director-General has issued a call for action to eliminate cervical cancer as a public health problem. To help inform global efforts, we modelled potential human papillomavirus (HPV) vaccination and cervical screening scenarios in low-income and lower-middle-income countries (LMICs) to examine the feasibility and timing of elimination at different thresholds, and to estimate the number of cervical cancer cases averted on the path to elimination. METHODS: The WHO Cervical Cancer Elimination Modelling Consortium (CCEMC), which consists of three independent transmission-dynamic models identified by WHO according to predefined criteria, projected reductions in cervical cancer incidence over time in 78 LMICs for three standardised base-case scenarios: girls-only vaccination; girls-only vaccination and once-lifetime screening; and girls-only vaccination and twice-lifetime screening. Girls were vaccinated at age 9 years (with a catch-up to age 14 years), assuming 90% coverage and 100% lifetime protection against HPV types 16, 18, 31, 33, 45, 52, and 58. Cervical screening involved HPV testing once or twice per lifetime at ages 35 years and 45 years, with uptake increasing from 45% (2023) to 90% (2045 onwards). The elimination thresholds examined were an average age-standardised cervical cancer incidence of four or fewer cases per 100 000 women-years and ten or fewer cases per 100 000 women-years, and an 85% or greater reduction in incidence. Sensitivity analyses were done, varying vaccination and screening strategies and assumptions. We summarised results using the median (range) of model predictions. FINDINGS: Girls-only HPV vaccination was predicted to reduce the median age-standardised cervical cancer incidence in LMICs from 19·8 (range 19·4-19·8) to 2·1 (2·0-2·6) cases per 100 000 women-years over the next century (89·4% [86·2-90·1] reduction), and to avert 61·0 million (60·5-63·0) cases during this period. Adding twice-lifetime screening reduced the incidence to 0·7 (0·6-1·6) cases per 100 000 women-years (96·7% [91·3-96·7] reduction) and averted an extra 12·1 million (9·5-13·7) cases. Girls-only vaccination was predicted to result in elimination in 60% (58-65) of LMICs based on the threshold of four or fewer cases per 100 000 women-years, in 99% (89-100) of LMICs based on the threshold of ten or fewer cases per 100 000 women-years, and in 87% (37-99) of LMICs based on the 85% or greater reduction threshold. When adding twice-lifetime screening, 100% (71-100) of LMICs reached elimination for all three thresholds. In regions in which all countries can achieve cervical cancer elimination with girls-only vaccination, elimination could occur between 2059 and 2102, depending on the threshold and region. Introducing twice-lifetime screening accelerated elimination by 11-31 years. Long-term vaccine protection was required for elimination. INTERPRETATION: Predictions were consistent across our three models and suggest that high HPV vaccination coverage of girls can lead to cervical cancer elimination in most LMICs by the end of the century. Screening with high uptake will expedite reductions and will be necessary to eliminate cervical cancer in countries with the highest burden. FUNDING: WHO, UNDP, UN Population Fund, UNICEF-WHO-World Bank Special Program of Research, Development and Research Training in Human Reproduction, Canadian Institute of Health Research, Fonds de recherche du Québec-Santé, Compute Canada, National Health and Medical Research Council Australia Centre for Research Excellence in Cervical Cancer Control.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In a comparative modelling analysis using three independent transmission-dynamic models, high-coverage girls-only HPV vaccination was projected to eliminate cervical cancer in most of 78 LMICs by the end of the century, with screening accelerating and extending elimination. Adding twice-lifetime screening was projected to achieve elimination in all 78 LMICs under all three thresholds and avert 74·1 million cases by 2120.
Key findings
- Girls-only HPV vaccination reduced median age-standardised cervical cancer incidence in LMICs from 19·8 (range 19·4–19·8) to 2·1 (2·0–2·6) cases per 100 000 women-years over the next century (89·4% [86·2–90·1] reduction), averting 61·0 million (60·5–63·0) cases.
- Adding twice-lifetime screening reduced incidence to 0·7 (0·6–1·6) cases per 100 000 women-years (96·7% [91·3–96·7] reduction) and averted an extra 12·1 million (9·5–13·7) cases; overall, intensive vaccination plus twice-lifetime screening was estimated to avert 74·1 million (70·4–75·1) cases by 2120.
- Girls-only vaccination was predicted to eliminate cervical cancer in 60% (58–65) of LMICs at the ≤4 cases per 100 000 women-years threshold, 99% (89–100) at ≤10, and 87% (37–99) at ≥85% reduction; adding twice-lifetime screening reached 100% (71–100) for all three thresholds. Where vaccination alone sufficed, elimination occurred between 2059 and 2102, and screening accelerated elimination by 11–31 years.
- Countries with the highest incidence (>25 cases per 100 000 women-years, mainly in sub-Saharan Africa) were not predicted to eliminate by vaccination alone; screening was required, and long-term vaccine protection was necessary for elimination.
Methods
- WHO Cervical Cancer Elimination Modelling Consortium comparative modelling analysis using three independently developed transmission-dynamic models (HPV-ADVISE, Harvard, Policy1-Cervix) selected by predefined criteria, projecting cervical cancer incidence for 78 LMICs from 2020 to 2120.
- Base-case scenarios: girls-only vaccination at age 9 years (catch-up to age 14 years), 90% coverage, 100% efficacy against HPV types 16, 18, 31, 33, 45, 52, and 58, lifelong protection; plus once-lifetime screening at age 35 years or twice-lifetime screening at ages 35 and 45 years, using HPV testing with uptake 45% (2023), 70% (2030), and 90% (2045 onwards), 100% treatment efficacy, and 10% loss to follow-up.
- Outcomes were age-standardised cervical cancer incidence, relative reduction versus status quo, and cases averted; elimination thresholds were ≤4 and ≤10 cases per 100 000 women-years and ≥85% reduction; results reported as median (range) across models, with sensitivity analyses varying vaccination and screening assumptions.
Limitations
- Stated: projections span >100 years, over which demographic, behavioural, and technological changes are anticipated; population growth affects cases averted (62 million with low UN population projections and 88 million with high projections versus 74 million base-case) but is expected to have minimal impact on age-standardised elimination timing, while changing sexual behaviour could lengthen time to elimination.
- Stated: the analysis assumes intensive scale-up and 90% vaccination and screening uptake; slower scale-up would delay elimination and reduce cases averted but would not affect whether elimination can be achieved.
- Stated: models omit plausible HIV–HPV biological interactions, potentially overestimating vaccination impact in high HIV prevalence settings (5 of 78 LMICs have HIV prevalence ≥10%), and rely on GLOBOCAN incidence estimates that may be underestimated, which could delay elimination. Evident: base-case assumptions of 100% vaccine efficacy, lifelong protection, 100% treatment efficacy, and only 10% loss to follow-up are idealized relative to real-world implementation, though sensitivity analyses partially address duration of protection and coverage.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
73 Own result · 30 Own interpretation · 9 No full text of the sources · 8 Partly supported · 6 Sources not found · 6 Own method · 6 No basis given · 3 Supported · 3 Supported so far · 1 Not supported · 1 Not checked yet · accuracy not yet measured
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“about 10% of cervical cancers are due to HPV types that are not in the currently available HPV vaccines10”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
What the sources say
- Disputedcites [10] Serrano B Alemany L Tous S Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease Infect Agent Cancer 7 2012 38 23273245 PMC3554470 sourceExperimental — accuracy not yet measured
The Background identifies the then-current licensed vaccines as targeting HPV 16/18, which account for about 70% of cervical cancers. The Discussion says coverage would rise to almost 90% with five additional types in a nine-valent vaccine under development. The roughly 10% figure therefore applies to that proposed vaccine, not the currently available vaccines. (LLM, conf=0.92)
Checked by a reasoning model — may be wrong.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This is particularly important since current HPV vaccination and cervical screening uptake is very low in most low-income and sub-Saharan African countries.2, 3, 4, 5”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
What the sources say
- Not matchedcites [2] PATH Global HPV Vaccine Introduction Overview: projected and current national introductions, demonstration/pilot projects, gender-neutral vaccination programs, and global HPV vaccine introduction maps (2006–2022) https://www.path.org/resources/global-hpv-vaccine-introduction-overview/ November, 2019
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [3] WHO Immunization, vaccines and biologicals: data, statistics and graphics https://www.who.int/immunization/monitoring_surveillance/data/en/
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites [4] Gakidou E Nordhagen S Obermeyer Z Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities PLoS Med 5 2008 e132 18563963 PMC2429949 sourceExperimental — accuracy not yet measured
The Abstract reports low cervical screening coverage in developing countries—19% on average—and Our Findings report effective coverage of 1% or less in Ethiopia. These findings support the screening portion, but the paper does not report HPV vaccination uptake or establish that both forms of uptake are very low in most low-income and sub-Saharan African countries. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Our results are consistent in part because the key drivers of our predictions (eg, achievability and timing of elimination) are country-specific baseline cervical cancer incidence and percentage of cancers due to the HPV vaccine types, which were based on the same data sources.1, 10”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
What the sources say
- Not checked — no full text of the sourcecites [1] Bray F Ferlay J Soerjomataram I Siegel RL Torre LA Jemal A Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 2018 394 424 30207593 source
- Partly supportedcites [10] Serrano B Alemany L Tous S Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease Infect Agent Cancer 7 2012 38 23273245 PMC3554470 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Thirdly, our models do not include plausible biological interactions between HIV and HPV (eg, HPV acquisition and disease progression might be increased among people living with HIV).51”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
What the sources say
- Supportedcites [51] Looker KJ Ronn MM Brock PM Evidence of synergistic relationships between HIV and Human Papillomavirus (HPV): systematic reviews and meta-analyses of longitudinal studies of HPV acquisition and clearance by HIV status, and of HIV acquisition by HPV status J Int AIDS Soc 21 2018 e25110 PMC5989783 29873885 source
The Introduction states that HPV acquisition and disease progression may be increased among people with immunodeficiencies, including those caused by HIV. The citation supports the biological-interaction example; the statement about what the citing authors’ own models omit is not attributed to this source. Page numbers were not supplied. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Finally, our country-specific cervical cancer incidence data are based on GLOBOCAN estimates,42, 53 which, where possible, are derived from extrapolation of recent trends in incidence obtained from national or subnational population-based cancer registries.”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
What the sources say
- Not matchedcites [42] Ferlay J Ervik M Lam F Global Cancer Observatory: cancer today 2018 International Agency for Research on Cancer Lyon, France https://gco.iarc.fr/today
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites [53] Ferlay J Colombet M Soerjomataram I Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods Int J Cancer 144 2019 1941 1953 30350310 sourceExperimental — accuracy not yet measured
The ‘Estimates of cancer incidence by country’ section says GLOBOCAN predicted 2018 rates from recent national incidence data for 45 countries. It also used subnational registry data, but describes using recent rates as proxies or modelling incidence from mortality—not extrapolating recent subnational incidence trends. The source therefore supports the general description but not that specific account of the subnational method. (LLM, conf=0.85)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and in 87% (37–99) of LMICs based on the 85% or greater reduction threshold.”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Abstract > Findings
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When adding twice-lifetime screening, 100% (71–100) of LMICs reached elimination for all three thresholds.”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Abstract > Findings
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and averted an extra 12·1 million (9·5–13·7) cases.”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Abstract > Findings
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Long-term vaccine protection was required for elimination.”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Abstract > Findings
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adding twice-lifetime screening reduced the incidence to 0·7 (0·6–1·6) cases per 100 000 women-years (96·7% [91·3–96·7] reduction)”
- Also stated in: § Results · plain
“HPV vaccination and twice-lifetime screening was predicted to reduce the average age-standardised cervical cancer incidence to 0·7 (0·6–1·6) cases per 100 000 women-years at equilibrium (96·7% [91·3–96·7] reduction).”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Abstract > Findings
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
- It may state two separate claims as one. 31
- Probably not a substantial claim. 16
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Large international randomised control clinical trials have shown that HPV vaccines are safe and highly effective against vaccine-type persistent infection and cervical precancerous lesions in women (with vaccine efficacy ≥93%).6, 7, 8”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Introduction
What the sources say
- Not checked — no full text of the sourcecites [6] Garland SM Hernandez-Avila M Wheeler CM Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases N Engl J Med 356 2007 1928 1943 17494926 source
- Not checked — no full text of the sourcecites [7] Paavonen J Naud P Salmeron J Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women Lancet 374 2009 301 314 19586656 source
- Supportedcites [8] Joura EA Giuliano AR Iversen OE A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women N Engl J Med 372 2015 711 723 25693011 source
The Incidence of Disease section reports 96.0% efficacy against persistent infection and 96.3% efficacy against high-grade cervical disease associated with HPV types 31, 33, 45, 52, and 58 in the per-protocol population, compared with the quadrivalent vaccine. The Adverse Events section reports generally similar systemic adverse-event rates, though injection-site events were more frequent with the 9-valent vaccine. These findings support the citing sentence for the 9-valent vaccine under the trial’s conditions. (LLM, conf=0.90)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“These vaccines target high-risk HPV types that cause about 70% (bivalent and quadrivalent vaccines: HPV types 16 and 18) and 90% (9-valent vaccine: HPV types 16, 18, 31, 33, 45, 52, and 58) of cervical cancers.9, 10”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Introduction
What the sources say
- Not checked — no full text of the sourcecites [9] de Sanjose S Quint WG Alemany L Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study Lancet Oncol 11 2010 1048 1056 20952254 source
- Supportedcites [10] Serrano B Alemany L Tous S Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease Infect Agent Cancer 7 2012 38 23273245 PMC3554470 source
The Results (Cervical cancer) report that HPV 16/18 account for almost 70% of cervical cancers worldwide and the five additional high-risk types account for 18.5%, bringing their combined contribution to about 90%. The vaccine also includes HPV 6/11, but the paper says those types add only 0.1% to the cervical-cancer estimate. (LLM, conf=0.93)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“These vaccines target high-risk HPV types that cause about 70% (bivalent and quadrivalent vaccines: HPV types 16 and 18) and 90% (9-valent vaccine: HPV types 16, 18, 31, 33, 45, 52, and 58) of cervical cancers.9, 10”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Introduction
What the sources say
- Not checked — no full text of the sourcecites [9] de Sanjose S Quint WG Alemany L Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study Lancet Oncol 11 2010 1048 1056 20952254 source
- Supportedcites [10] Serrano B Alemany L Tous S Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease Infect Agent Cancer 7 2012 38 23273245 PMC3554470 source
The Background states that Cervarix targets HPV 16/18, which cause about 70% of cervical cancer cases, and that Gardasil targets those same two cancer-causing types. The Results (Cervical cancer) also report that HPV 16/18 account for almost 70% worldwide. (LLM, conf=0.94)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Finally, mathematical modelling studies have consistently shown that girls-only HPV vaccination and cervical cancer screen-and-treat programmes are cost-effective in LMICs.17, 18, 19, 20, 21, 22”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Introduction
What the sources say
- Not checked — no full text of the sourcecites [17] Jit M Brisson M Portnoy A Hutubessy R Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study Lancet Glob Health 2 2014 e406 e414 25103394 source
- Partly supportedcites [18] Jit M Brisson M Potential lives saved in 73 countries by adopting multi-cohort vaccination of 9–14-year-old girls against human papillomavirus Int J Cancer 143 2018 317 323 29446090 PMC6001440 sourceExperimental — accuracy not yet measured
The Discussion says routine HPV vaccination is cost-effective in almost all countries and suggests that vaccinating additional cohorts of girls could have a similar cost-effectiveness profile. The paper does not establish the cost-effectiveness of cervical cancer screen-and-treat programmes in LMICs, so it supports only the vaccination part of the cited sentence. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [19] Fesenfeld M Hutubessy R Jit M Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review Vaccine 31 2013 3786 3804 23830973 source
- Supportedcites [20] Campos NG Sharma M Clark A The health and economic impact of scaling cervical cancer prevention in 50 low- and lower-middle-income countries Int J Gynaecol Obstet 138 suppl 1 2017 47 56 28691334 source
The Abstract and §3.2 describe model-based estimates for HPV vaccination of 10-year-old girls and screening with treatment when needed for 35-year-old women in 50 low- and lower-middle-income countries. Section 3.2 finds both very cost-effective and says its vaccination estimate is consistent with published literature; it also reports cost-effective screen-and-treat findings from other analyses. (LLM, conf=0.93)
- Not matchedcites [21] Campos NG Tsu V Jeronimo J Mvundura M Lee K Kim JJ When and how often to screen for cervical cancer in three low- and middle-income countries: a cost-effectiveness analysis Papillomavirus Res 1 2015 38 58
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [22] Canfell K Shi JF Lew JB Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies Vaccine 29 2011 2487 2494 21211586 source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
Every source the paper cites for this claim was checked and supports it.
In the paper
“This comparative modelling analysis adhered to recently published guidelines for multi-model comparisons28 and for reporting model-based analyses of HPV vaccination and cervical screening29 (appendix pp 26–28).”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Methods > Comparative modelling approach
What the sources say
- Supportedcites [28] den Boon S Jit M Brisson M Guidelines for multi-model comparisons of the impact of infectious disease interventions BMC Med 17 2019 163 31422772 PMC6699075 source
The Background section identifies this paper as presenting guidelines for multi-model comparisons of infectious disease interventions, which is what citation 28 identifies. The claim of adherence concerns the citing authors’ own analysis; the separate HPV reporting guidelines are attributed to citation 29, not this source. (LLM, conf=0.91)
- Supportedcites [29] Canfell K Kim JJ Kulasingam S HPV-FRAME: a consensus statement and quality framework for modelled evaluations of HPV-related cancer control Papillomavirus Res 8 2019 100184 PMC6804684 31505258 source
The citation to HPV-FRAME is attached to the guidelines for reporting model-based analyses of HPV vaccination and cervical screening, not to the separate multi-model-comparison guidelines. Domain 6 describes reporting standards for cervical screening models, including models that combine screening and vaccination. The citing authors’ assertion that their own analysis adhered to those standards is not something this source establishes. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Outcomes are presented with the median (range) of the predictions of the three models to represent between-model uncertainty.28”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Methods > Outcomes
What the sources say
- Supportedcites [28] den Boon S Jit M Brisson M Guidelines for multi-model comparisons of the impact of infectious disease interventions BMC Med 17 2019 163 31422772 PMC6699075 source
The ‘Presenting and pooling results > Good practice’ section describes reporting the median with minimum and maximum model estimates to show variability between model predictions. The reference to three models describes the citing authors’ application of that method, not a requirement attributed to the guideline. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Furthermore, combining cervical screening with HPV vaccination has been predicted to be cost-effective across several LMICs.20, 21, 22”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
What the sources say
- Partly supportedcites [20] Campos NG Sharma M Clark A The health and economic impact of scaling cervical cancer prevention in 50 low- and lower-middle-income countries Int J Gynaecol Obstet 138 suppl 1 2017 47 56 28691334 sourceExperimental — accuracy not yet measured
Section 3.2 reports that vaccination and screening were each estimated to be very cost-effective across the countries studied. But Section 2.2 says the paper calculated cost-effectiveness ratios separately and did not examine screening in vaccinated women, so it does not establish the cost-effectiveness of combining the interventions in the same population. (LLM, conf=0.87)
- Not matchedcites [21] Campos NG Tsu V Jeronimo J Mvundura M Lee K Kim JJ When and how often to screen for cervical cancer in three low- and middle-income countries: a cost-effectiveness analysis Papillomavirus Res 1 2015 38 58
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [22] Canfell K Shi JF Lew JB Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies Vaccine 29 2011 2487 2494 21211586 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“First, we used a comparative modelling approach including three models that have been extensively peer reviewed and validated with post-vaccination surveillance data.30, 31, 32, 33, 34, 35, 36”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
What the sources say
- Not checked — no full text of the sourcecites [30] Van de Velde N Boily MC Drolet M Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis J Natl Cancer Inst 104 2012 1712 1723 23104323 source
- Not checked — no full text of the sourcecites [31] Brisson M Laprise JF Drolet M Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study Vaccine 31 2013 3863 3871 23830974 source
- Partly supportedcites [32] Burger EA Campos NG Sy S Regan C Kim JJ Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country Vaccine 36 2018 4823 4829 29807710 PMC6066173 sourceExperimental — accuracy not yet measured
The Methods (Analytic overview; page unavailable) describe a three-tiered approach linking Harvard-HPV, Harvard-CC, and Harvard-Scale Up. The paper does not say that these three models were extensively peer reviewed or validated against post-vaccination surveillance data; the Methods (Simulation models; page unavailable) describe calibration to Ugandan epidemiological outcomes, which is not the same claim. (LLM, conf=0.88)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“First, our projections are for more than 100 years, a period over which substantial demographic and behavioural changes and technological development are anticipated that can have an impact on cervical cancer incidence.43, 49”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
What the sources say
- Not checked — no full text of the sourcecites [43] UN Department of Economic and Social Affairs World population prospects: 2017 revision https://population.un.org/wpp/Download/Standard/Population/ 2017 source
- Partly supportedcites [49] Baussano I Lazzarato F Brisson M Franceschi S Human papillomavirus vaccination at a time of changing sexual behavior Emerg Infect Dis 22 2016 18 23 26691673 PMC4696692 sourceExperimental — accuracy not yet measured
The Results (page unavailable) project that changing sexual behavior can increase HPV16 prevalence, supporting the concern that behavior may affect long-term projections. The paper does not project cervical cancer incidence over more than 100 years or address anticipated demographic changes and technological development. In the citing sentence, “our projections” refers to the citing authors’ work, not this source’s projections. (LLM, conf=0.83)
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In these countries (mainly in Asia), age-adjusted HPV infection and cervical cancer rates might be increasing,49 and thus time to elimination might be slightly longer than predicted.”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
What the sources say
- Partly supportedcites [49] Baussano I Lazzarato F Brisson M Franceschi S Human papillomavirus vaccination at a time of changing sexual behavior Emerg Infect Dis 22 2016 18 23 26691673 PMC4696692 sourceExperimental — accuracy not yet measured
The Results model an increase in HPV16 prevalence from 3% to 8% as sexual behavior changes, using rural India as an example of a traditional population. The cited paper does not establish increasing age-adjusted HPV infection rates across mainly Asian countries or increasing cervical cancer rates. The sentence’s prediction about time to elimination follows the citation and is not treated as attributed to this source. (LLM, conf=0.83)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the context of high-coverage girls-only vaccination, adding a third lifetime screen (to HPV vaccination and twice-lifetime screening) was predicted to provide very small additional gains in cervical cancer prevention, and only slightly accelerated time to elimination.”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Results
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“HPV vaccination alone was predicted to result in elimination in all regions in the world, except for sub-Saharan Africa, where 27% (range 24–37) of countries would reach elimination, and Latin America and Caribbean, where 80% (80–80) of countries would reach elimination.”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Results
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A sensitivity analysis examining the impact of screening suggests that although twice-lifetime screening without HPV vaccination would substantially reduce cervical cancer incidence, the age-standardised cervical cancer incidence would remain higher than four cases per 100 000 women-years in the countries examined (appendix pp 10–11).”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Results
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“our sensitivity analysis showed that the duration of protection and the number of types included in the HPV vaccine can affect whether girls-only HPV vaccination with twice-lifetime screening leads to cervical cancer elimination (appendix pp 10–11).”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Results
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the models predicted that multi-age cohort vaccination up to age 25 years would substantially accelerate the declines in cervical cancer incidence, but would not change cervical cancer incidence at equilibrium (appendix pp 10–11).”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Results
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“our models predicted that HPV vaccination and twice-lifetime screening will avert 49·9 million (range 49·5–50·9) cases in sub-Saharan Africa over the next century, which represents about 70% of all cases averted in LMICs.”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Results
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The sensitivity analysis suggests that a small reduction in HPV vaccination coverage from 90% to 80% would have little impact on the decline in cervical cancer incidence in the first 30 years following girls-only HPV vaccination (without screening), but would lead to slightly higher long-term incidence (appendix pp 10–11).”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Results
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“When producing projections with low population predictions from the UN,43 we estimated that 62 million cervical cancer cases would be averted with the triple-intervention global elimination strategy, and that 88 million cases would be averted with the UN's high population predictions, versus 74 million cases with base-case projections (appendix p 12).”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
What the sources say
- Not checked — no full text of the sourcecites [43] UN Department of Economic and Social Affairs World population prospects: 2017 revision https://population.un.org/wpp/Download/Standard/Population/ 2017 source
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- The authors state this as an assumption: Intensive scale-up and 90% uptake of HPV vaccination and cervical screening.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The models predicted that all vaccination strategies will achieve elimination, except for girls-only vaccination with 80% coverage.”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Results
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Additionally, cervical cancer elimination can be achieved in all but three LMICs (in sub-Saharan Africa) with once-lifetime screening and in all LMICs with twice-lifetime screening.”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- The authors state this as an assumption: Intensive scale-up and 90% uptake of HPV vaccination and cervical screening.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our results suggest that including screening in addition to HPV vaccination would substantially increase the number of cervical cancer cases averted and would accelerate elimination, mainly by preventing cases in older, unvaccinated women.”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- The authors state this as an assumption: Intensive scale-up and 90% uptake of HPV vaccination and cervical screening.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Multi-age cohort vaccination up to 25 years of age was predicted to substantially accelerate elimination and avert additional cervical cancer cases but would have no effect on whether a country reaches elimination, which is only determined by long-term routine vaccination coverage.”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- The authors state this as an assumption: Intensive scale-up and 90% uptake of HPV vaccination and cervical screening.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In doing so, cervical cancer incidence would be reduced by 97% and more than 74 million cases would be averted over the next century.”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“These countries have the highest burden of cervical cancer (incidence >25 per 100 000 women-years) and are mostly in sub-Saharan Africa.”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
plaincorrelationaln = 4- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the triple-intervention strategy was chosen as the global elimination strategy as it would accelerate elimination by 11–31 years and prevent an additional 12 million cervical cancer cases over the next century (compared with vaccination alone).”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- The authors state this as an assumption: Intensive scale-up and 90% uptake of HPV vaccination and cervical screening.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In conclusion, our comparative modelling analysis suggests that cervical cancer elimination as a public health problem is possible by the end of the century, resulting in a 97% reduction in cervical cancer incidence in LMICs.”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- The authors state this as an assumption: Intensive scale-up and 90% uptake of HPV vaccination and cervical screening.
In the paper
“Cervical cancer is the second most frequent cancer among women in low-income and lower-middle-income countries (LMICs).1”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Bray F Ferlay J Soerjomataram I Siegel RL Torre LA Jemal A Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 2018 394 424 30207593 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The model predictions were done independently by each group and collated by the study's coordinating centre (Laval University, Québec, QC, Canada).”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Methods > Outcomes
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Finally, all models were calibrated to highly stratified sexual behaviour and epidemiological data, validated to clinical trials or post-vaccination data, or both, and reproduce the age-specific cervical cancer incidence estimates from the Global Cancer Observatory (GLOBOCAN) 2018 for all 78 LMICs42”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Methods > Model description
What the sources say
- Not matchedcites [42] Ferlay J Ervik M Lam F Global Cancer Observatory: cancer today 2018 International Agency for Research on Cancer Lyon, France https://gco.iarc.fr/today
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Impact predictions were done without harmonising the basic structure of the models or parameters governing the setting and disease.”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Methods > Comparative modelling approach
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, countries with the highest cervical cancer incidence at present (>25 cases per 100 000 women-years), more than 90% of which are in sub-Saharan Africa, would not reach elimination by vaccination alone.”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our findings suggest that to achieve global elimination by the end of the century, these targets need to be met in the countries with the highest burden of cervical cancer, and these countries also need to be supported to scale up twice-lifetime screening from 70% to 90% by 2045.”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- The authors state this as an assumption: Intensive scale-up and 90% uptake of HPV vaccination and cervical screening.
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“Additionally, the modelling results were presented and discussed at multiple WHO advisory group and global stakeholder meetings.24, 39, 48”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
What the sources say
- Not matchedcites [24] WHO Draft: global strategy towards eliminating cervical cancer as a public health problem https://www.who.int/docs/default-source/cervical-cancer/cervical-cancer-elimination-strategy.pdf?sfvrsn=8a083c4e_0 Dec 16, 2019
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [39] WHO Immunization and Vaccine-related Implementation Research Advisory Committee (IVIR-AC) recommendations. Sept 2018 Wkly Epidemiol Rec 94 2019 5 16
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [48] WHO Strategic Advisory Group of Experts on Immunization. Working Group on human papillomavirus (HPV) immunization—conclusions and recommendations https://www.who.int/immunization/sage/meetings/2018/october/3_SAGE2018_WG_recommendation_FINAL.pdf?ua=1 Sept 27–28, 2018
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
None of the sources cited for this claim have been checked yet.
In the paper
“This strategy was chosen as it is the recommended strategy by the WHO Strategic Advisory Group of Experts on Immunization (SAGE)41 and a large body of evidence shows that it is highly cost-effective in LMICs and high-income countries.17, 19, 31, 32”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
What the sources say
- Not matchedcites [41] WHO Immunization, vaccines and biologicals: human papillomavirus (HPV) https://www.who.int/immunization/diseases/hpv/en/
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [17] Jit M Brisson M Portnoy A Hutubessy R Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study Lancet Glob Health 2 2014 e406 e414 25103394 source
- Not checked — no full text of the sourcecites [19] Fesenfeld M Hutubessy R Jit M Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review Vaccine 31 2013 3786 3804 23830973 source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
- Not matched
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“SAGE recommended in October, 2019, that multi-age cohort catch-up vaccination for girls aged 10–14 years should be postponed to alleviate the demand for vaccine doses in the coming years.”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Second, key knowledge users from WHO were involved in all aspects of the study, from its design to interpretations of findings.”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Our comparative modelling analysis, which includes projections from three independent transmission-dynamic models”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“The two base-case screening strategies examined, primary HPV screen-and-treat testing with once-lifetime and twice-lifetime screening, were chosen as they are the recommended strategies by WHO.40”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
What the sources say
- Not matchedcites [40] WHO Early diagnosis and screening: cervical cancer https://www.who.int/cancer/prevention/diagnosis-screening/cervical-cancer/en/
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“To achieve cervical cancer elimination in all 78 LMICs, our models predict that scale-up of both girls-only HPV vaccination and twice-lifetime screening is necessary, with 90% HPV vaccination coverage, 90% screening uptake, and long-term protection against HPV types 16, 18, 31, 33, 45, 52, and 58.”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“many countries have cervical cancer incidence higher than 40 cases per 100 000 women-years.1”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
What the sources say
- Not checked — no full text of the sourcecites [1] Bray F Ferlay J Soerjomataram I Siegel RL Torre LA Jemal A Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 2018 394 424 30207593 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For these countries, high cervical screening uptake will have to be sustained for elimination to be maintained (or additional types would have to be included in future HPV vaccines).”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The recommendations were partly based on results from HPV-ADVISE showing that these strategies would produce similar benefits to girls-only vaccination at age 9 years with a 1-year catch-up for girls aged 10–14 years.46”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
What the sources say
- Not matchedcites [46] Brisson M Jit M Bénard É Optimal HPV immunization strategies in the context of limited resources & vaccine supply. WHO-SAGE meeting https://www.who.int/immunization/sage/meetings/2019/october/brisson_hpv_sage_october_2019.pdf Oct 9, 2019
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Not matched
In the paper
“By not capturing such interactions, our models might overestimate the impact of HPV vaccination in high HIV prevalence settings (five of 78 LMICs have HIV prevalence ≥10%52).”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
What the sources say
- Not matchedcites [52] WHO Global Health Observatory data repository. Number of people (all ages) living with HIV, estimates by country http://apps.who.int/gho/data/view.main.22100?lang=en
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Sexual behaviour has been changing in many LMICs, from a more traditional pattern of sexual behaviour, with a lower reported number of lifetime partners and wider age gaps between partners, to a more sex-similar pattern of behaviour, where both sexes have a similar and higher number of partners and narrow age gaps.”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“If scale-up is slower than modelled, this would delay the predicted timing of elimination and reduce the number of cancer cases averted, but it would not affect whether or not elimination can be achieved.”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Specific prevention strategies might be required for people living with HIV to accelerate cervical cancer elimination in high HIV prevalence settings.”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Discussion
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence. The paper’s conclusions may not depend on it.
The authors state this as an assumption.
HPV vaccines are prophylactic and vaccination produces post-vaccination herd effects.
“All models assume that HPV vaccines are prophylactic and capture post-vaccination herd effects.”
The authors state this as an assumption.
Countries follow SAGE recommendations.
“assuming countries follow SAGE recommendations”
The authors state this as an assumption.
Supply constraints are relieved over the next decade.
“provided supply constraints are relieved over the next decade”
The authors state this as an assumption.
Intensive scale-up and 90% uptake of HPV vaccination and cervical screening.
“we assumed intensive scale-up and 90% uptake of HPV vaccination and cervical screening.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although HPV vaccination of adolescent girls will help in reducing cervical cancer incidence in low- and middle-income countries (LMICs) by more than 85% over the next century [4], adult women who do not benefit by the preventive HPV vaccines need immediate intervention of cervical cancer screening and appropriate management of pre-cancers to prevent cervical cancers.”
From Performance of HPV Self-Sample Collected by a Novel Kit in Comparison with Clinician Collected Sample for Cervical Cancer Screening (2024) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our projections also support previous modelling studies2, 31, 32 that found high coverage of vaccination against HPV16 and HPV18 in girls aged 10 years could reduce the burden of cervical cancer in India considerably, and enable the country to reach the WHO elimination target even with single-dose vaccination.”
From Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study (2022) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Using GLOBOCAN estimates would make reaching the WHO elimination threshold more difficult, but should still be possible under high vaccine coverage and efficacy.2, 31”
From Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study (2022) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Yet, cervical cancer could be eliminated as a public health problem with appropriate preventive measures.2”
From Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study (2022) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Screening with high uptake will expedite reductions and will be necessary to eliminate cervical cancer in countries with the highest burden.”
From HPV self-sampling for cervical cancer screening: a systematic review of values and preferences (2021) · cites this paper as [98]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Results
“2073 (2078–2079)”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Results
“Data are median (range) predictions from three dynamic models.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Results
“Low-income and lower-middle-income countries (n=44)”
§ Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries > Results
“All low-income and lower-middle-income countries (n=78)”
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Self-citationEstimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2019) · International Journal of Cancer · doi:10.1002/ijc.31937 · Cited by 7,553
Self-citationde Sanjose, S., Quint, W. G., Alemany, L., Geraets, D. T., Klaustermeier, J. E., Lloveras, B., Tous, S., Felix, A., Bravo, L. E., Shin, H.-R., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70230-8 · Cited by 2,728
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., Tang, G. W. K., Ferris, D. G., Steben, M., Bryan, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061760 · Cited by 1,886
Ronco, G., Dillner, J., Elfström, K. M., Tunesi, S., Snijders, P. J. F., Arbyn, M., Kitchener, H., Segnan, N., Gilham, C., Giorgi-Rossi, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62218-7 · Cited by 1,810
Paavonen, J., Naud, P., Salmerón, J., Wheeler, C., Chow, S.-N., Apter, D., Kitchener, H., Castellsague, X., Teixeira, J., Skinner, Sr., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61248-4 · Cited by 1,655
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
Joura, E. A., Giuliano, A. R., Iversen, O.-E., Bouchard, C., Mao, C., Mehlsen, J., Moreira, E. D., Ngan, Y., Petersen, L. K., Lazcano-Ponce, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1405044 · Cited by 1,433
Drolet, M., Bénard, É., Pérez, N., Brisson, M., Ali, H., Boily, M.-C., Baldo, V., Brassard, P., Brotherton, J. M. L., Callander, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30298-3 · Cited by 1,384
Self-citationHPV Screening for Cervical Cancer in Rural India
Sankaranarayanan, R., Nene, B. M., Shastri, S. S., Jayant, K., Muwonge, R., Budukh, A. M., Hingmire, S., Malvi, S. G., Thorat, R., Kothari, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808516 · Cited by 1,278
Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities
Gakidou, E., Nordhagen, S., & Obermeyer, Z. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050132 · Cited by 976
Research works printed but not linked: 1
- 2019, Immunization and Vaccine-related Implementation Research Advisory Committee (IVIR-AC) recommendations. Sept 2018, Wkly Epidemiol Rec, 94, 5
Cited by
Sorted by citations
Items 201–300 of 947
Zhao, X., Zhao, S., Xia, C., Hu, S., Duan, X., Liu, Z., Wang, Y., You, T.-T., Gao, M., Qiao, Y., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-02840-8 · Cited by 18
Lubeya, M. K., Chibwesha, C. J., Mwanahamuntu, M., et al. (2023) · Vaccines · doi:10.3390/vaccines11050912 · Cited by 17
“The HPV vaccine is safe and effective for the primary prevention of cervical cancer, which has high morbidity and mortality in sub-Saharan Africa (SSA) [8].”
BackgroundZewdie, A., Kasahun, A. W., Habtie, A., et al. (2023) · BMC Public Health · doi:10.1186/s12889-023-16305-3 · Cited by 17
“HPV vaccination offers an opportunity for developing nations to decrease the burden of cervical cancer [13].”
BackgroundSuehiro, T. T., Damke, G. M. Z. F., Damke, E., Ramos, P. L. R. D. A., Silva, M. D. A. P., Pelloso, S. M., Huh, W. K., Franco, R., da Silva, V. R. S., Scarinci, I. C., et al. (2020) · Infectious Agents and Cancer · doi:10.1186/s13027-020-00301-y · Cited by 19
“With the appropriate vaccination rate thresholds, this vaccine provides a logical rationale for increasing screening intervals considering the anticipated decrease in the burden of disease [15].”
BackgroundDolciami, M., Capuani, S., Celli, V., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12040638 · Cited by 17
Ontor, M. Z. H., Ali, M. M., Hossain, S. S., et al. (2022) · International Conference on Advances in Electrical, Computing, Communication and Sustainable Technologies (ICAECT) · doi:10.1109/icaect54875.2022.9807871 · Cited by 17
“It is the fourth hazardous cancer among all the existing cancer types [1].”
BackgroundXie, L., Ren, J., Min, S., Zhu, X., Xu, D., Qiao, K., Chen, X., Liu, M., Xiao, Z., & Tan, Y. (2023) · Vaccine · doi:10.1016/j.vaccine.2022.12.027 · Cited by 19
Aleezada, Z. N., Patel, I., & Yusuf, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125581 · Cited by 19
Grulich, A. E., Mercer, C. H., Sturrock, B. R., Baral, S., Turpin, N., Phanuphak, N., Rowley, J. T., Wi, T., Gemzell‐Danielsson, K., Garcia‐Moreno, C., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01188-2 · Cited by 18
Self-citationPark, S. J., Wai, A., Pavithran, K., Kunheri, B., & Valsraj, K. M. (2021) · Psycho-Oncology · doi:10.1002/pon.5796 · Cited by 16
“The inequalities for cancer treatment can be observed from diagnosis, time taken to receive relevant treatment or chemotherapy, radiation, surgery and clinical trial participation.(63,64) The SMI patients who have schizophrenia or mental conditions that involve psychosis face the most discrimination.”
BackgroundResultInfluentialSmith, D. L., & Perkins, R. B. (2022) · Preventive Medicine · doi:10.1016/j.ypmed.2022.107070 · Cited by 16
“Statistical models indicate the possibility of eliminating cervical cancer within the next century, but rely on achieving vaccination rates of 80% (Brisson et al., 2020).”
Jemal, Z., Chea, N., Hasen, H., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0286262 · Cited by 16
“For instance, the World Health Organization designed a 90–70–90 triple-intervention strategy aimed to achieve 90% HPV vaccination coverage, 70% of women being screened at least twice in their lifetime, and 90% of women having access to cervical pre-cancer and cervical cancer treatment and palliative care services by 2…”
Wan, Z., Zhao, J., Xu, L., Sun, P., Shuai, P., Li, K., Zhang, Y., Chen, Y., Su, Q., Yao, X., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28891 · Cited by 19
Xiao, T., Wang, C., Yang, M., Yang, J., Xu, X., Shen, L., Zhou, Y., Xing, H., & Ou, C. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.26890 · Cited by 16
“Gravidity (median [IQR], 2 [2-3] for <CIN3 vs 3 [2-4] for CIN3+; P = .”
Faqih, L., Alzamil, L., Aldawood, E., et al. (2023) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed8120511 · Cited by 16
“In developed nations, increased awareness of HPV screening has led to a decline in cervical cancer incidence [17,18].”
BackgroundHuman papillomavirus prevalence and dynamics
Sait, K., Anfinan, N. M., Sait, H. K., et al. (2024) · Saudi Medical Journal · doi:10.15537/smj.2024.45.3.20230824 · Cited by 16
Chen, X., Xu, T. S., Wu, J., et al. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2388347 · Cited by 16
“Insights from Gillison et al., 18 which emphasized the global impact of educational efforts on vaccine acceptance, and Brewer and Fazekas, 19 which highlighted the critical role of government intervention and information dissemination in vaccine acceptance, support the need for a comprehensive…”
BackgroundPeng, Y., Tang, Q., Wu, S., & Zhao, C. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-10851-4 · Cited by 29
“Despite the significant reduction in CC incidence in some countries due to the promotion of vaccination and screening programs, the disease remains prevalent in resource-limited areas [2].”
Gottschlich, A., Rivera‐Andrade, A., Bevilacqua, K., Murchland, A. R., Isak, E., Álvarez, C. S., Ogilvie, G. S., Carey, T. E., Prince, M. E., Dean, M. C., et al. (2020) · BMC Public Health · doi:10.1186/s12889-020-09478-8 · Cited by 15
“As such, in resourceconstrained settings, it is likely that even 1–2 lifetime HPV tests would significantly decrease rates of cervical cancer [18].”
BackgroundMicroRNA‑186‑3p attenuates tumorigenesis of cervical cancer by targeting MCM2
Lu, X., Song, X., Hao, X., Liu, X., Zhang, X., Yuan, N., Ma, H., & Zhang, Z. (2021) · Oncology Letters · doi:10.3892/ol.2021.12800 · Cited by 17
“Although HPV infection has been demonstrated to be the main cause of cervical cancer, several unknown oncogenes promote cervical cancer progression (37).”
BackgroundParents attitudes toward the human papilloma virus (HPV) vaccine
Hendaus, M. A., Hassan, M., Alsulaiti, M., et al. (2021) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1122_20 · Cited by 16
Cost-effectiveness analysis of quadrivalent and nonavalent human papillomavirus vaccines in Ethiopia
Wondimu, A., Postma, M. J., & van Hulst, M. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.02.080 · Cited by 16
Nanotechnology based vaccines: Cervical cancer management and perspectives
Jasrotia, R., Dhanjal, D. S., Bhardwaj, S., Sharma, P., Chopra, C., Singh, R., Kumar, A., Mubayi, A., Kumar, D., Kumar, R., et al. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103351 · Cited by 16
Muresu, N., Sotgiu, G., Marras, S., Gentili, D., Sechi, I., Cossu, A., Dettori, A., Pietri, R., Paoni, L., Ghi, M. E., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19020693 · Cited by 15
“In line with WHO call for action to eliminate cervical cancer as a public health problem [34] future multicenter studies could better estimate HPV risk-factors, as well as those which play a role in the progression of disease to plan more adequate preventive strategies.”
BackgroundYagi, A., Ueda, Y., Nakagawa, S., et al. (2022) · Vaccines · doi:10.3390/vaccines10091455 · Cited by 15
“suggested that high HPV vaccination coverage of girls can lead to cervical cancer elimination in most lower-middle-income countries by the end of the century [14].”
BackgroundRao, D. W., Broshkevitch, C. J., Gui, L., Chikandiwa, A. T., Sharma, M., Hathaway, C., Tan, N., Mugo, N., & Barnabas, R. V. (2022) · Journal of the International AIDS Society · doi:10.1002/jia2.26021 · Cited by 15
“Time to elimination is defined by the years at which estimated cancer incidence crosses the threshold of 4 cases per 100,000 woman-years (elimination as a public health problem) and a higher threshold of 10 cases per 100,000 [4, 29].”
BackgroundChoi, C., Leung, K. S. M., Chan, K. K. L., Bai, Y., Jit, M., & Wu, J. T. K. (2023) · BMC Medicine · doi:10.1186/s12916-023-02748-3 · Cited by 16
Self-citationSong, Y., Shou, X., Sheng, B., Mei, J., Shi, K., Shang, L., & Zhu, X. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202202904 · Cited by 15
Malawian caregivers’ experiences with HPV vaccination for preadolescent girls: A qualitative study
Moucheraud, C., Whitehead, H. S., Songo, J., Szilagyi, P. G., Hoffman, R. M., & Kaunda-Khangamwa, B. N. (2023) · Vaccine X · doi:10.1016/j.jvacx.2023.100315 · Cited by 16
“Modeling studies highlight that reaching this goal would vastly reduce cervical cancer burden in low- and middle-income countries over the next century [2,3].”
BackgroundGuimarães, E. L., Chissaque, A., Pecenka, C. J., Debellut, F., Schuind, A., Vaz, B., Banze, A., Rangeiro, R., Mariano, A. A. N., Lorenzoni, C. F., et al. (2023) · Vaccines · doi:10.3390/vaccines11061058 · Cited by 15
“HPV vaccines have now been introduced in over 100 countries worldwide [13], with several studies demonstrating favorable cost-effectiveness [6,14,15].”
BackgroundEwongwo, A. N., Sahor, A. F., Ngwa, W. F., & Nwachukwu, C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1380663 · Cited by 15
Cohee, L. M., Halliday, K. E., Gelli, A., Mwenyango, I., Fernando Lavadenz, M., Burbano, C., Drake, L., & Bundy, D. A. P. (2020) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.20-0779 · Cited by 16
“Models predict that 90% coverage could reduce the incidence of cervical cancer in women aged < 45 years by 85% in the next 30 years.(22) Integrated deliverywith other school-based health interventions could support achieving this level of coverage.”
BackgroundObol, J. H., Lin, S., Obwolo, M. J., Harrison, R., & RICHMOND, R. L. (2021) · BMC Health Services Research · doi:10.1186/s12913-021-06795-5 · Cited by 14
“Globally, cervical cancer incidence and mortality is disproportionately distributed with the highest burden falling among low-and-middle income countries (LMICs) of the world, particularly in regions such as sub-Saharan Africa (SSA), Southern and South-Eastern Asia, South America and the Caribbean [2–4].”
BackgroundInfluentialJi, L., Yao, Y., Yu, D., Chen, W., Yin, S., Yun, F., Tang, S., & Yao, L. (2024) · Journal of Medical Internet Research · doi:10.2196/51477 · Cited by 16
“The coverage of screening has a significant impact on cervical cancer incidence and mortality [34-36], so the high efficiency of AI technology also accelerates the process of achieving the goal of cervical cancer elimination.”
Cuello, M. A., Gómez‐Valenzuela, F., Wichmann, I. A., & Olawaiye, A. B. (2025) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.70279 · Cited by 15
“25,32,33,43 Furthermore, successful implementation of these recommendations requires a coordinated approach across multiple sectors, including education, social welfare, and environmental policies.”
The Quest to Eradicate HPV-Related Oropharyngeal Carcinoma: An Opportunity Not to Miss
Lalonde, C. S., Teng, Y., Burtness, B. A., Ferris, R. L., Ahmed, R., & Saba, N. F. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac098 · Cited by 14
Rodrigues, E. S., Mendes, E. D. T., & Nucci, L. B. (2023) · Vaccines · doi:10.3390/vaccines11030506 · Cited by 14
“A modelling study in 78 low-income and lower-middle-income countries (LMICs) showed that girls-only HPV vaccination would lead to cervical cancer elimination in most LMICs if high coverage is reached (>90% coverage) given that the vaccine provides long-term protection [6].”
MethodShinomiya, H., & Nibu, K. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02336-8 · Cited by 14
Du, H., Dai, W., Zhou, Q., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1290112 · Cited by 14
“Cervical cancer screening play an important role in eliminating cervical cancer (2, 3).”
BackgroundAmin, S. M., El‐Sayed, M. M., El‐Monshed, A. H., & Atta, M. H. R. (2025) · BMC Nursing · doi:10.1186/s12912-025-02797-4 · Cited by 21
“Currently, Egypt lacks a national screening program for CC, with Papanicolaou (PAP) smear screening considered potentially cost-inef-fective, given the comparatively low rates of CCS among Egyptian women when compared to Western countries [14].”
Fabian, A., Krug, D. A., & Alkatout, İ. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm10010093 · Cited by 14
Lehtinen, M., Gray, P. G., Louvanto, K., et al. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2064279 · Cited by 14
“which is a notoriously hard target due to its persistence [4,7].”
BackgroundGalani, A., Zikopoulos, A., Moustakli, E., Potiris, A., Paraskevaidi, M., Arkoulis, I., Machairoudias, P., Stavrakaki, S. M., Kyrgiou, M., & Stavros, S. (2025) · Cancers · doi:10.3390/cancers17193179 · Cited by 17
“For example, evidence suggests that screening could safely begin at age 30 and be performed every 10 years in women who received the HPV vaccine before sexual debut [76,77].”
Cervical Cancer Prevention in El Salvador: Gains to Date and Challenges for the Future
Alfaro, K. M., Soler, M., Maza, M., et al. (2022) · Cancers · doi:10.3390/cancers14112776 · Cited by 13
“4 million lives by 2070, and 62 million lives by 2120 [5].”
BackgroundJansen, E. E. L., de Kok, I. M. C. M., Kaljouw, S., Demirel, E., de Koning, H. J., & Hontelez, J. A. C. (2022) · BMC Medicine · doi:10.1186/s12916-022-02631-7 · Cited by 16
“Furthermore, screening can expedite elimination in LMICSs by up to 31 years [32].”
BackgroundArora, S., & Tuffaha, H. (2023) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13962 · Cited by 17
Lin, Y., Wang, C., He, X., Yao, Q.-M., & Chen, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1345942 · Cited by 14
Chen, Q., Zhao, J., Xue, X., et al. (2024) · BMC Women s Health · doi:10.1186/s12905-024-02907-5 · Cited by 13
“Although the incidence of cervical cancer has been suppressed due to human papillomavirus(HPV)vaccination and cervical cancer screening in many countries and regions [2], there is still a large number of people who die from cervical cancer each year [3].”
BackgroundFan, X., He, W., Zhang, Q., Zhang, B., Dong, L., Li, L., & Liu, X. (2024) · Cancer Control · doi:10.1177/10732748241232324 · Cited by 13
Silva, T. C., Barral‐Netto, M., & Boaventura, V. S. (2025) · The Lancet Global Health · doi:10.1016/s2214-109x(25)00279-7 · Cited by 16
Population-Level Effectiveness and Herd Protection 17 Years After HPV Vaccine Introduction
DeSieghardt, A., Ding, L., Ermel, A. C., Franco, E. L., Dagnall, C. L., Brown, D. R., Yao, S., & Kahn, J. A. (2025) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2025.3568 · Cited by 14
PIWI proteins and piRNAs in cervical cancer: a propitious dart in cancer stem cell-targeted therapy
Kunnummal, M., Angelin, M., & Das, A. V. (2021) · Human Cell · doi:10.1007/s13577-021-00590-4 · Cited by 13
Progress and challenges in human papillomavirus and cervical cancer in southern Africa
Ramogola‐Masire, D., Luckett, R. L., & Dreyer, G. (2021) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000805 · Cited by 13
“However, recommendations rely heavily on modeling instead of primary data [11], which constrain their broad applicability, particularly to sub-Saharan Africa.”
BackgroundBurger, E. A., Laprise, J., Sy, S., Regan, M. C., Prem, K., Jit, M., Brisson, M., & Kim, J. J. (2022) · International Journal of Cancer · doi:10.1002/ijc.34054 · Cited by 13
“Given the decades-long natural history of HPV infection to cervical cancer, understanding the timing of the future cervical cancer burden under alternative implementation scenarios requires the use of mathematical simulation models, which have been used to support the planning of the WHO's elimination goals.(2) Using…”
BackgroundMethodInfluentialSelf-citationMolecular triaging options for women testing HPV positive with self-collected samples
Taghavi, K., Zhao, F., Downham, L., Baena, A., & Basu, P. S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1243888 · Cited by 15
ThinPrep cytology combined with HPV detection in the diagnosis of cervical lesions in 1622 patients
Husaiyin, S., Jiao, Z., Yimamu, K., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0260915 · Cited by 13
“HPV infection is the primary cause of precancerous lesions and cervical cancer; high-risk HPV (HR-HPV) infection is the main risk factor for high-grade CIN and cervical cancer, which has been evidenced by research on both pathogenesis and vaccines [4, 10, 11].”
BackgroundPrem, K., Choi, Y. H., Bénard, É., Burger, E. A., Hadley, L., Laprise, J., Regan, M. C., Drolet, M., Sy, S., Abbas, K., et al. (2021) · medRxiv · doi:10.1101/2021.02.08.21251186 · Cited by 13
Self-citationDevelopment of Enzymatic Recombinase Amplification Assays for the Rapid Visual Detection of HPV16/18
Ding, N., Qi, W., Wu, Z., et al. (2023) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2304.04009 · Cited by 12
“However, some low/middle-income countries (LMICs) still lack effective screening programs, and approximately 88% of CC cases in 2020 occurred in these areas [8, 9].”
Epidemiology of cervical cancer and HPV infection in Asia and Oceania
Ueda, Y. (2024) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.15943 · Cited by 12
Moucheraud, C., Ochieng, E., Ogutu, V., Chang, L. C., Golub, G. M., Crespi, C. M., & Szilagyi, P. G. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126410 · Cited by 16
“[2 – 4] Although many low-and middle-income countries (LMICs) have introduced national programs for HPV vaccination, uptake remains low.”
Single-dose human papillomavirus vaccination: an update
Kreimer, A. R., Watson‐Jones, D., Kim, J. J., & Dull, P. M. (2024) · JNCI Monographs · doi:10.1093/jncimonographs/lgae030 · Cited by 14
Self-citationBrotherton, J. M. L., Vajdic, C. M., & Nightingale, C. E. (2025) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2025.2451732 · Cited by 14
“…parameters for vaccine implementation, then a universal both sex vaccination program would unsurprisingly maximise the disease burden prevented [78], could facilitate eventual elimination (e.g. over 70 years +) of vaccine targeted HPV types in a population at a coverage of 80%+ in both sexes…”
Zhang, T., & Xiaohan, C. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104712 · Cited by 12
Obol, J. H., Harrison, R., Lin, S., Obwolo, M. J., & RICHMOND, R. L. (2020) · BMC Public Health · doi:10.1186/s12889-020-09482-y · Cited by 13
Bizzarri, N., Anchora, L. P., Zannoni, G. F., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01384-z · Cited by 12
Portnoy, A., Sweet, S., Desalegn, D., Memirie, S. T., Kim, J. J., & Verguet, S. (2021) · Health Policy and Planning · doi:10.1093/heapol/czab052 · Cited by 16
“We used a previously validated static cohort model approach to estimate the number of CC cases and deaths averted associated with routine HPV vaccination in Ethiopia (Goldie et al., 2008; Lee et al., 2013; Campos et al., 2017; Ozawa et al., 2017; Brisson et al., 2020; Burger et al., 2020; Canfell et al., 2020).”
MethodSelf-citationThe diagnostic accuracy of TCT + HPV-DNA for cervical cancer: systematic review and meta-analysis
Li, T., Lai, Y. C., & Yuan, J. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-1732 · Cited by 12
HPV vaccination: Intention to participate among female senior high school students in Ghana
Ampofo, A. G., Mackenzie, L., & Boyes, A. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.11.007 · Cited by 13
Shrestha, A. D., Gyawali, B., Shrestha, A., Shrestha, S., Neupane, D., Ghimire, S., Campbell, C., & Kallestrup, P. (2021) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000670 · Cited by 16
“…(HPV) causes almost all cervical cancers, and hence the disease is largely preventable through a comprehensive approach that includes effective screening and treatment and prophylactic vaccine (Gaffikin et al., 2003; Denny et al., 2005; Sankaranarayanan et al., 2007; Brisson et al., 2020).”
BackgroundBizzarri, N., Anchora, L. P., Kucukmetin, A., et al. (2021) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2021.04.009 · Cited by 12
Cervical cancer prevention: Human papillomavirus testing as primary screening
Desai, S., Zhu, M. J., & Lapidos‐Salaiz, I. (2021) · Cancer · doi:10.1002/cncr.34006 · Cited by 11
“Results from a modeling study suggest high uptake of screening will have to be sustained in combination with HPV vaccinations, because approximately 10% of cervical cancer cases in Sub- Saharan Africa are caused by HPV types currently not supported by the vaccine.(17) As more countries adapt and implement the updated…”
BackgroundSustaining communicable disease elimination efforts in the Americas in the wake of COVID-19
Espinal, M., Alonso, M., Sereno, L. S., et al. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100313 · Cited by 11
Dong, L., Nygård, M., Støer, N. C., Klungsøyr, O., & Hansen, B. T. (2023) · International Journal of Cancer · doi:10.1002/ijc.34489 · Cited by 14
“To date more than 100 countries have included HPV vaccination of preadolescent girls in their national immunization programs.(3,9) The HPV vaccine can also be delivered through catch-up programs and by opportunistic vaccination outside a program.”
BackgroundSLC5A3 is important for cervical cancer cell growth
Li, L., Shen, F., Cheng, Q., Sun, J. P., Li, H., Sun, H.-T., Cai, X., Chen, M., Yang, B., Wang, L., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.84570 · Cited by 12
“Human papillomavirus (HPV) vaccines, cervical cancer screening, and advances in diagnosis and adjuvant treatments have contributed to the decreased incidence of cervical cancer, especially in developed countries [3, 36, 37].”
BackgroundEpidemiological aspects of the incidence and mortality of cervical cancer (literature review)
Кулиева, Г. З., Сирекановна, М. Л., Krikunova, L. I., Иванов, С. А., & Каприн, А. Д. (2023) · Tumors of female reproductive system · doi:10.17650/1994-4098-2023-19-3-77-84 · Cited by 11
Park, D. H., Haizan, I., Ahn, M. J., Choi, M. Y., Kim, M. J., & Choi, J. (2024) · Biosensors · doi:10.3390/bios14010026 · Cited by 11
“The ambitious goals for 2030 included attaining 90% HPV vaccination coverage, ensuring that 70% of women are screened twice in their lifetime, and providing 90% of women access to treatment and palliative care for cervical pre-cancer and cancer [13,14].”
BackgroundReid, F., Adams, T., Adel, R. S., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0298154 · Cited by 11
“In addition, many LMICs have prioritised certain cancers in women such as breast and cervical cancer where screening could have a major impact on mortality [14, 15].”
BackgroundFerroptosis and circular RNAs: new horizons in cancer therapy
Bhat, A. A., Kukreti, N., Afzal, M., Goyal, A., Thapa, R., Ali, H., Shahwan, M. J., Almalki, W. H., Kazmi, I. A., Alzarea, S. I., et al. (2024) · EXCLI journal · doi:10.17179/excli2024-7005 · Cited by 12
Deciphering the sex gap in global life expectancy: the impact of female-specific cancers 1990-2019
Trias‐Llimós, S., Rentería, E., Rutigliano, R., Aggarwal, A. K., Moodley, J., Unger‐Saldaña, K., & Soerjomataram, I. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae191 · Cited by 11
MYSM1 attenuates osteoarthritis by recruiting PP2A to deubiquitinate and dephosphorylate RIPK2
Wei, K., Zhou, C., Shu, Z., et al. (2025) · Bone Research · doi:10.1038/s41413-024-00368-y · Cited by 11
“20 The involvement of MYSM1 in OA pathogenesis, however, has not been elucidated.”
Sevilla, J. P. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102243 · Cited by 11
Breast Cancer: Impact of New Treatments?
Storme, G. A. (2023) · Cancers · doi:10.3390/cancers15082205 · Cited by 13
“HPV influences prognosis in cervix cancer and others including head and neck cancers; it has been perceived in many other cancers including breast [16,17].”
BackgroundGhantasala, G. S. P., Hùng, B. T., & Chakrabarti, P. (2023) · International Conference on Computer Communication and Informatics (ICCCI) · doi:10.1109/iccci56745.2023.10128454 · Cited by 12
“When this has been known, premature diagnosis of breast as well as cervical cancers is correlated with upgraded prognostic and longevity [9, 10].”
BackgroundHuang, S., Qi, Y., Chen, S., He, B., Chen, X., & Xu, J. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1022030 · Cited by 11
M6A modification regulates tumor suppressor DIRAS1 expression in cervical cancer cells
Wang, Y., Ye, L.-H., Zhao, A., et al. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2306674 · Cited by 11
Motaze, N. V., Mthombothi, Z. E., Adetokunboh, O., et al. (2021) · Vaccines · doi:10.3390/vaccines9020084 · Cited by 11
“Achieving at least 80% coverage as recommended by WHO [16] avoids this negative effect of rubella vaccines, and countries planning RCV introduction should adhere to this recommendation.”
BackgroundInfluentialNasioudis, D., Byrne, M. E., Ko, E. M., et al. (2021) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2021-002543 · Cited by 11
Tewari, P., Kashdan, E., Walsh, C., et al. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009289 · Cited by 11
Porchia, B. F. M. M., Aps, L. R. M. M., Moreno, A. C. R., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.56644 · Cited by 11
“Human papillomavirus (HPV) infections cause almost 570,000 cases per year of invasive cervical cancer worldwide [1].”
BackgroundHopfer, S., Phillips, K. K.-D., Weinzierl, M., Vasquez, H. E., Alkhatib, S., & Harabagiu, S. M. (2022) · Frontiers in Digital Health · doi:10.3389/fdgth.2022.819228 · Cited by 13
“HPV Vaccination as a Highly Effective Cancer Prevention Measure The HPV vaccination, federally licensed in 2006, is highly effective at preventing high-grade and persistent cervical intraepithelial neoplasia in women and ismore than 92% effective at preventing HPV-associated cancers, including cervical, anal, and orop…”
BackgroundOptimal vaccine allocation for the control of sexually transmitted infections
Saldaña, F., Steindorf, V., Srivastav, A. K., Stollenwerk, N., & Aguiar, M. (2023) · Journal of Mathematical Biology · doi:10.1007/s00285-023-01910-y · Cited by 9
“These early female-only HPV immunization programs have been found to be cost-effective when cervical cancer prevention is the main objective (see Brisson et al (2020) and the references therein) .”
BackgroundHall, M. T., Hyatt, A., Smith, M. A., Torode, J., Costa, T., Nguyen, D., Balshaw, T., Grogan, P. B., Sweeny, K., Auste, C., et al. (2025) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2025.101423 · Cited by 13
Self-citationGlobal status of HPV vaccination two decades in: effective, safe and preventing cancer
Brotherton, J. M. L., LaMontagne, D. S., & Bloem, P. N. (2025) · Expert Review of Vaccines · doi:10.1080/14760584.2025.2609869 · Cited by 12
Self-citationLi, F., Wang, Y., Jin, Y., et al. (2024) · International Journal of Women s Health · doi:10.2147/ijwh.s446768 · Cited by 10
“While early screening and vaccination programs have effectively reduced the number of new cases in many countries, 8–10 numbers of new cases and related deaths remain high in developing countries.”
BackgroundGhasemi, M., Savabi-Esfahani, M., Noroozi, M., & Satari, M. (2024) · BMC Cancer · doi:10.1186/s12885-024-12098-9 · Cited by 12
“Despite the recommendation, only 60% of women in developed countries and 20% of women in developing countries undergo the Pap smear test, according to studies [8, 15].”
BackgroundShamsi, U. S., Zahid, F., Jabbar, A. B. A., Musharraf, M., Gauhar, F., Akbar, I., Sherwani, M., Bhatti, W., Chaudhary, E., Sadiq, S., et al. (2024) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2024.25.3.813 · Cited by 21
“According to a study that modelled various countries, it is possible to eliminate cervical cancer worldwide by vaccinating only girls with a highly effective 9-valent HPV vaccine at a coverage rate of 80-100% coupled with twice-lifetime screening for HPV [7].”
BackgroundPrem, K., Cernuschi, T., Malvolti, S., Brisson, M., & Jit, M. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102735 · Cited by 10
Self-citationSemprini, J., Zahnd, W. E., & Brandt, H. M. (2025) · The Journal of Rural Health · doi:10.1111/jrh.12915 · Cited by 10
Dlamini, Z., Alaouna, M., Marutha, T., Mkhize‐Kwitshana, Z. L., Mbodi, L., Chauke-Malinga, N., Luvhengo, T. E., Marima, R. M., Hull, R., Skepu, A., et al. (2025) · Cancers · doi:10.3390/cancers17152537 · Cited by 13
“In Rwanda, a national HPV vaccination program achieving over 90% coverage among adolescent girls has been instrumental in decreasing cervical cancer incidence, especially when paired with routine screening initiatives [150].”
Deng, Z., Mao, X., Yang, Y., Wu, G., Meng, H., Hou, J., Yu, X., Zhou, W., Mao, G., & Ma, Y. (2025) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2025.117960 · Cited by 11
Metadata
- Authors
- Brisson, M., Kim, J. J., Canfell, K., Drolet, M., Gingras, G., Burger, E. A., Martin, D., Simms, K. T., Bénard, É., Boily, M.-C., Sy, S., Regan, C., Keane, A., Caruana, M., Nguyen, D. T. N., Smith, M. A., Laprise, J.-F., Jit, M., Alary, M., Bray, F., Fidarova, E., Elsheikh, F., Bloem, P. J. N., Broutet, N., & Hutubessy, R.
- Affiliations
- Université Laval (CA)
- Harvard University (US)
- The University of Sydney (AU)
- Centre de recherche du CHU de Québec-Université Laval (CA)
- Public Health England (GB)
- Institut National de Santé Publique du Québec (CA)
- Centre international de recherche sur le cancer (FR)
- World Health Organization (CH)
- Corresponding author
- Brisson, Marc
- ORCID
- Brisson, Marc
- Kim, Jane J
- Canfell, Karen
- Drolet, Mélanie
- Gingras, Guillaume
- Burger, Emily A
- Martin, Dave
- Simms, Kate T
- Bénard, Élodie
- Boily, Marie-Claude
- Sy, Stephen
- Keane, Adam
- Caruana, Michael
- Nguyen, Diep T N
- Smith, Megan A
- Laprise, Jean-François
- Jit, Mark
- Alary, Michel
- Bray, Freddie
- Fidarova, Elena
- Broutet, Nathalie
- Hutubessy, Raymond
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 395
- Issue
- 10224
- Pages
- 575-590
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC7043009
- OpenAlex
- W3003249044
- Semantic Scholar
- 86b4018633d5c25bf1575a9cf09520869a994585
- Cited by
- 943
- References
- 37
- Citations by year
- 2026: 131 · 2025: 174 · 2024: 177 · 2023: 147 · 2022: 126 · 2021: 137 · 2020: 50
- FWCI
- 70.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- Spiral (Imperial College London) (submittedVersion, other-oa)
- Funders
- European Union (MR/R015600/1)
- Topics
- Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Keywords
- cervical cancer elimination, HPV vaccination, cervical cancer screening, cervical cancer incidence, vaccination coverage, screening uptake, incidence reduction, case averted
- MeSH terms
- Adult, Uterine Cervical Neoplasms, Developing Countries, Feasibility Studies, Female, Humans, Income, Mass Screening, Models, Biological, Vaccination, Incidence, Papillomavirus Infections, Papillomavirus Vaccines, Early Detection of Cancer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-16, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-16 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
